Early stage, rapid, low-cost, and accurate detection of disease components in a biological fluid is critically important. A point of care device can use functionalized magnetic beads to facilitate this detection. The device can include a sample holder with a collection region. A magnet can be used to draw the functionalized nanoparticles bound to the disease component into the collection region, where the disease component is captured. A light source can shine a light beam through the collection region; and a detector can detect the light beam after traversing the collection region to determine whether the disease component is present in the sample.

Disclosed herein is a molecular imprinted air filter for removing, detecting and/or reporting specific agents and/or molecules and comprising one or more air-permeable layers of molecular imprinted material positioned to contact molecules and/or agents in an airborne, and/or microdroplet-borne environment, a bioactive molecular imprint of a molecule that captures a specific airborne, fluid borne, and/or microdroplet-borne molecule, particle, or agent, and an electronic enhancement.

A system and method is provided for detecting an analyte within a sample. The method includes providing a first electromagnetic radiation to the sample in a manner that resonantly excites mechanical vibrations in the analyte. The method also includes providing a second electromagnetic radiation to the sample so as to interact with vibrating analyte, wherein a third electromagnetic radiation is produced based on the interaction. The method further includes receiving the a third electromagnetic radiation and determining the presence of the analyte based on the received a third electromagnetic radiation.

Disclosed herein are methods for diagnosing or prognosticating SARS-CoV-2 infection and/or COVID-19 in a subject. The methods set forth improved immunoassays, sensing platforms, and methods for detecting SARS-CoV-2 infection and re-infection.

Proteases of Group IV (+)ssRNA viruses were found to act on a human sequences in addition to the viral sequences. The identity of the cleavable human sequences is disclosed. Detection of these sequences can act as a diagnostic of infection. It is contemplated that these findings could be employed to facilitate post-translational silencing at the level of protein (e.g., removal of existing proteins), thus serving as a protein analog to CRISPR/Cas9 and RNAi/RISC, and further to enable sequence-specific silencing of host functions without the modification of the host genome.

The present invention provides systems, devices, and methods for point-of-care and/or distributed testing services. The methods and devices of the invention are directed toward automatic detection of analytes in a bodily fluid. The components of the device can be modified to allow for more flexible and robust use with the disclosed methods for a variety of medical, laboratory, and other applications. The systems, devices, and methods of the present invention can allow for effective use of samples by improved sample preparation and analysis.

A method for a pre-symptomatic diagnosis of a viral illness in a subject is provided. The method may include obtaining a biological sample that includes at least one peripheral blood mononuclear cell from a subject prior to the subject experiencing any symptoms associated with the viral illness. The method may further include extracting proteins from the biological sample. The method may also include analyzing the extracted proteins, via mass spectrometry, for the presence of a predefined viral protein biomarker associated with the viral illness. If the predefined viral protein biomarker is present, the subject is diagnosed with the viral illness prior to experiencing the symptoms associated with the viral illness.

Flow cell devices, cartridges, and systems are described that provide reduced manufacturing complexity, lowered consumable costs, and flexible system throughput for nucleic acid sequencing and other chemical or biological analysis applications. The flow cell device can include a capillary flow cell device or a microfluidic flow cell device.

Systems and methods are provided for sample processing. A device may be provided, capable of receiving the sample, and performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing multiple assays. The device may comprise one or more modules that may be capable of performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing the steps using a small volume of sample.

This disclosure relates to portable devices for detecting various virus antibodies for the detection of virus diseases. Viral infections, such as those from SARS-CoV family viruses, HIV family viruses, and other family viruses can be detected by their antibodies or DNA in a clinical specimen.